What Is GLP-1? How It Works, Medications, Side Effects, and What You Should Know

Key Takeaways

GLP-1 is a naturally occurring incretin hormone produced by L-cells in the small intestine within minutes of eating. It works through three parallel mechanisms: stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release from alpha cells, and slowing gastric emptying to increase satiety. A comprehensive 2025 systematic review spanning PubMed, Embase, and Cochrane found GLP-1 receptor agonists deliver HbA1c reductions of 1.5–2.0% in type 2 diabetes, 7–24% body weight loss in obesity treatment, and 14–20% reduction in major adverse cardiovascular events (Emerging Frontiers in GLP-1 Therapeutics, PMC 2025). Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common reason people discontinue treatment. A 2026 analysis of over 9,000 patients found that those who stopped semaglutide or tirzepatide regained an average of nearly 2 pounds per month (Stanford Medicine, 2026).

GLP-1, short for glucagon-like peptide-1, is a hormone your body produces naturally. It belongs to a class of hormones called incretins, which are released by cells in your small intestine after you eat. In healthy digestion, GLP-1 tells the pancreas to release insulin (lowering blood sugar), tells the liver to stop dumping glucose into the bloodstream, slows the rate at which food leaves your stomach (so you feel full longer), and signals the brain's hypothalamus to reduce appetite. This is the normal machinery. It runs quietly in the background every time you eat.

What made GLP-1 a cultural phenomenon is not the hormone itself but the drugs that mimic it. Pharmaceutical GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others — bind to the same receptors but last far longer than natural GLP-1 (which your body breaks down within 2–3 minutes). The result is a sustained version of your body's own appetite and blood-sugar regulation, producing weight loss that was previously achievable only through bariatric surgery. As of mid-2026, roughly 11% of American adults are using a GLP-1 medication for weight loss, up from 3% in 2024, and 91% are aware these drugs exist (Gallup National Health and Well-Being Index, July 2026). This guide covers how GLP-1 works, the medications available, their side effects, who they are and are not for, and the nutritional considerations that come with using them.

A quick disclosure: YourHealthier sells a GLP-1 Companion supplement formulated to support nutritional needs during GLP-1 therapy. This guide is not a sales pitch for that product; it is an objective overview of GLP-1 biology, the prescription medications, and the evidence behind them.

How does GLP-1 work in the body?

Your body's GLP-1 system operates on a simple feedback loop: you eat, L-cells in your intestinal lining detect nutrients (especially glucose and fats), and they secrete GLP-1 into the bloodstream. From there, GLP-1 acts on three targets simultaneously.

Pancreas. GLP-1 binds to receptors on beta cells and stimulates insulin secretion, but only when blood glucose is elevated. This glucose-dependent mechanism is why GLP-1 drugs carry a lower risk of hypoglycemia than older diabetes medications like sulfonylureas, which stimulate insulin regardless of blood sugar levels. GLP-1 also suppresses glucagon secretion from alpha cells, reducing the liver's glucose output.

Stomach. GLP-1 slows gastric emptying, the rate at which food moves from the stomach into the small intestine. This is the mechanism behind the prolonged fullness that GLP-1 drug users describe. It is also the mechanism behind the most common side effect: nausea. The stomach is holding food longer than the brain expects.

Brain. GLP-1 receptors exist in the hypothalamus and brainstem areas that regulate appetite and reward. Activation of these receptors reduces hunger signals and, according to emerging research, may dampen the hedonic (pleasure-driven) aspects of eating, which is why some users report reduced cravings not just for food but for alcohol and nicotine as well.

The critical limitation of natural GLP-1 is its half-life: roughly 2–3 minutes. An enzyme called DPP-4 (dipeptidyl peptidase-4) rapidly degrades it. This is why the hormone works as a meal-by-meal signal rather than a sustained force. GLP-1 receptor agonist drugs solve this by modifying the molecule's structure to resist DPP-4 degradation, extending the half-life from minutes to days (for injectable semaglutide, approximately 7 days), which is why they are dosed weekly rather than with every meal.

What are the types of GLP-1 medications?

GLP-1 receptor agonists have evolved through three generations, each with improved efficacy and convenience. All are prescription medications. None are available over the counter.

First generation: short-acting

Exenatide (Byetta) was the first GLP-1 receptor agonist approved by the FDA in 2005. It requires twice-daily injection and produces modest weight loss (2–4% of body weight; FDA prescribing information). A longer-acting version, Bydureon, moved to once-weekly dosing. These are now rarely prescribed for weight management given the availability of more effective options, but remain in use for type 2 diabetes.

Second generation: long-acting

Liraglutide is available as Victoza (for type 2 diabetes) and Saxenda (for weight management, FDA-approved 2014). It requires daily injection and produces approximately 5–8% body weight loss (FDA prescribing information). Dulaglutide (Trulicity) is a once-weekly injection approved for type 2 diabetes with demonstrated cardiovascular benefits.

Semaglutide represents the major clinical leap. It is available in three formulations: Ozempic — once-weekly injection, FDA-approved for type 2 diabetes (2017), widely prescribed off-label for weight loss before Wegovy's approval. Wegovy — once-weekly injection at a higher dose, FDA-approved specifically for chronic weight management (2021), clinical trials (STEP program) demonstrated approximately 15% body weight loss over 68 weeks. Rybelsus — oral tablet taken daily, FDA-approved for type 2 diabetes (2019), an oral formulation of Wegovy for weight management received FDA approval in early 2026. (STEP 1, NEJM).

Third generation: multi-receptor agonists

Tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, producing greater metabolic effects than GLP-1 alone: Mounjaro — once-weekly injection for type 2 diabetes (FDA-approved 2022). Zepbound — once-weekly injection for chronic weight management (FDA-approved 2023), clinical trials (SURMOUNT program) demonstrated up to 22.5% body weight loss, the highest of any approved anti-obesity medication. (SURMOUNT program).

Emerging candidates in late-stage development include CagriSema (semaglutide combined with cagrilintide, an amylin analog), retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors), and orforglipron (a non-peptide oral GLP-1 agonist that does not require the fasting restrictions of Rybelsus).

GLP-1 medication comparison (2026 FDA-approved drugs)

Medication	Active Ingredient	Route	Frequency	Approved For	Avg. Weight Loss
Ozempic	Semaglutide	Injection	Weekly	Type 2 diabetes	~10–14%
Wegovy	Semaglutide	Injection	Weekly	Weight management	~15%
Rybelsus	Semaglutide	Oral tablet	Daily	Type 2 diabetes	~5–8%
Mounjaro	Tirzepatide	Injection	Weekly	Type 2 diabetes	~15–20%
Zepbound	Tirzepatide	Injection	Weekly	Weight management	~20–22.5%
Saxenda	Liraglutide	Injection	Daily	Weight management	~5–8%

Efficacy figures reflect mean weight loss from pivotal trials (STEP program for semaglutide, SURMOUNT program for tirzepatide) and FDA prescribing information. Individual results vary by dose, duration, diabetes status, and adherence.

What are the most common GLP-1 side effects?

Gastrointestinal symptoms dominate. A 2026 safety review published in PMC found that GLP-1 receptor agonist therapy is associated with a consistent pattern of adverse events, with gastrointestinal effects being the most frequent and the primary driver of treatment discontinuation (PMC, 2026).

Nausea is the single most reported side effect, affecting 20–44% of users in clinical trials depending on the drug and dose (FDA prescribing information). It is dose-dependent (worse during titration) and usually improves over the first 4–8 weeks. The mechanism is straightforward: GLP-1 slows gastric emptying, and the stomach signals discomfort when food sits longer than expected.

Vomiting and diarrhea affect 10–25% and 15–20% of users, respectively. Like nausea, these tend to be worst during the initial dose-escalation phase and improve with time for most people. (FDA prescribing information).

Constipation is reported in 10–15% of users. Slower gastric emptying plus reduced food intake means less material moving through the GI tract, which can lead to harder, less frequent stools. (FDA prescribing information).

Reduced appetite is technically the intended therapeutic effect, not a side effect, but it warrants mention because the degree of appetite suppression can be more dramatic than many users expect. Some people describe a near-complete absence of hunger, especially at higher doses, which can lead to unintentional nutritional deficiencies if dietary intake drops too far without compensatory supplementation.

Less common but clinically important

Hair loss (alopecia) has emerged as a notable concern. A 2025 scoping review in Cureus identified over 1,000 spontaneous reports of hair loss in GLP-1 users filed with the U.S. FDA (Rojas Lopez et al., 2025, Cureus). The primary subtype identified is telogen effluvium, a form of diffuse hair shedding triggered by rapid weight loss and potential nutritional deficits (particularly protein, iron, zinc, and biotin) rather than a direct drug effect on hair follicles.

"Ozempic face" refers to facial volume loss (periorbital hollowing, nasolabial deepening) resulting from rapid fat loss, including from facial fat pads. A 2026 review described this as multifactorial: both weight-loss-related fat depletion and potential modulation of adipocyte differentiation by GLP-1 receptor activation (PMC, 2026).

Pancreatitis concerns have been largely addressed. The same 2026 PMC safety review noted that long-term clinical trial data have dispelled earlier concerns about GLP-1 receptor agonists raising the risk for acute pancreatitis or pancreatic cancer. However, these medications remain contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Mental health effects are under investigation. A 2025 European Psychiatry review explored theoretical mechanisms by which GLP-1 receptor agonists may alter mood, noting post-marketing reports of depression and suicidal ideation compared to metformin users (Stewart & Carr, 2025, European Psychiatry). The FDA has not established a causal link, and the evidence remains mixed, but patients with pre-existing mood disorders should discuss this with their prescribing physician.

Who is GLP-1 medication for (and who is it not for)?

GLP-1 receptor agonists are FDA-approved for two primary indications: type 2 diabetes (Ozempic, Mounjaro, Victoza, Trulicity, Rybelsus) to improve glycemic control, and chronic weight management (Wegovy, Zepbound) for adults with a BMI of 30+ or BMI 27+ with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.

Who should not use GLP-1 medications: individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); people with a history of pancreatitis (use with caution under supervision); pregnant or breastfeeding individuals (discontinue at least 2 months before planned pregnancy); individuals with severe gastroparesis or other GI motility disorders. GLP-1 medications are prescription drugs requiring medical evaluation, ongoing monitoring, and dose titration by a licensed healthcare provider. They are not supplements, not available over the counter, and not appropriate for people who simply want to lose a few pounds without a clinical indication.

What happens when you stop taking GLP-1?

Weight regain is the norm, not the exception. A large 2026 analysis of over 9,000 patients found that people who stopped semaglutide or tirzepatide regained an average of nearly 2 pounds per month. The STEP 1 trial extension, which followed patients for a year after stopping semaglutide, showed participants had regained two-thirds of their lost weight by the end of that year (Stanford Medicine, 2026).

This is not a failure of willpower. It reflects the biology: obesity is a chronic condition involving reset appetite set points, altered hormonal signaling, and metabolic adaptation. When the exogenous GLP-1 signal is removed, the underlying drivers of weight gain return. This is why most obesity medicine specialists frame GLP-1 medications as long-term or indefinite treatments (similar to blood pressure or cholesterol medications), not short courses. For those who do discontinue, maintaining weight loss requires aggressive lifestyle strategies: high protein intake (1.0–1.6 g per kg of body weight daily), consistent resistance training, and ongoing monitoring.

Do natural GLP-1 foods exist?

Your body produces GLP-1 naturally in response to eating, and certain foods and nutrients appear to stimulate GLP-1 release more than others. However, the magnitude of this natural stimulation is vastly smaller than what pharmaceutical GLP-1 agonists achieve, so "natural GLP-1 foods" should be understood as part of a healthy diet rather than an alternative to medication for anyone with a clinical indication.

Foods and nutrients associated with increased GLP-1 secretion include high-protein foods (eggs, Greek yogurt, lean meats, legumes), fiber-rich foods (oats, barley, vegetables, legumes) where soluble fiber is fermented by gut bacteria into short-chain fatty acids that stimulate L-cell GLP-1 secretion, healthy fats (avocado, olive oil, nuts), and fermented foods (yogurt, kefir, sauerkraut).

Berberine, a plant compound found in goldenseal and barberry, has been studied for its effects on glucose metabolism and has shown some evidence of increasing GLP-1 secretion in animal and small human studies. For a deeper look at this compound: berberine benefits and blood sugar support.

The honest synthesis: eating more protein, fiber, and healthy fats while reducing processed food and added sugar will support your body's natural GLP-1 production. It will not replicate the clinical effect of injectable semaglutide at 2.4 mg weekly. These are complementary strategies, not competing ones.

What nutritional gaps does GLP-1 medication create?

Reduced food intake on GLP-1 therapy creates predictable nutritional shortfalls that deserve attention. When you eat significantly less, you consume fewer micronutrients by default, even if your food choices are excellent.

Vitamin B12. GLP-1 receptor agonists slow gastric emptying and may reduce intrinsic factor availability, both of which impair B12 absorption. B12 deficiency can cause fatigue, cognitive fog, and peripheral neuropathy. Supplementation with methylcobalamin (the active form of B12) is a straightforward hedge.

Iron. Reduced food intake plus potential GI side effects can deplete iron stores, especially in menstruating women. Symptoms include fatigue, pallor, and exercise intolerance.

Zinc and magnesium. Both minerals are commonly under-consumed in the general population and become more so when total caloric intake drops. For more on magnesium: magnesium glycinate benefits.

Protein. This is the macronutrient deficiency with the most functional consequence during GLP-1 therapy. Reduced appetite means reduced protein intake, which combined with caloric deficit accelerates lean muscle loss. Stanford Medicine's GLP-1 guide recommends 100–140 grams of protein daily for a 200-pound person on GLP-1 therapy.

Biotin. Hair loss (telogen effluvium) during GLP-1 therapy is linked partly to rapid weight loss and partly to nutritional deficits including biotin, zinc, and iron. Supplementation may help mitigate this, though evidence is indirect.

A companion supplement formulated specifically for GLP-1 users addresses these gaps without requiring you to track each nutrient individually. For our formulation and the rationale behind each ingredient: best supplements for GLP-1 users.

How much do GLP-1 medications cost?

Cost has been the single largest barrier to GLP-1 access. Without insurance, brand-name GLP-1 list prices have historically topped $1,000 per month (KFF). Several developments in 2025–2026 have changed this landscape.

Brand-name pricing. In 2026, the U.S. government reached agreements with Novo Nordisk and Eli Lilly through the TrumpRx program, bringing the cash price of Ozempic, Wegovy, Mounjaro, and Zepbound to approximately $245 per month for eligible patients.

Compounded versions. Compounding pharmacies (503A and 503B facilities) have offered versions of semaglutide and tirzepatide at $200–$400 per month. However, the FDA began increasing enforcement against non-FDA-approved compounded GLP-1 products in February 2026, citing safety concerns. The long-term availability of compounded GLP-1 medications is uncertain.

Insurance coverage. Coverage varies dramatically. Most commercial insurers cover GLP-1 medications for type 2 diabetes but may require prior authorization. Coverage for weight management (Wegovy, Zepbound) is less consistent. Medicaid spending on GLP-1 drugs grew from approximately $1 billion in 2019 to $8.6 billion in 2024.

GLP-1 and exercise: what changes?

Resistance training becomes non-negotiable during GLP-1 therapy. In any caloric deficit, the body loses both fat and lean muscle mass. Without resistance training, a network meta-analysis of 22 RCTs found lean mass accounts for roughly 25% of total weight lost on GLP-1 drugs, with DXA substudies reporting a range of 26–40%.

Stanford Medicine's GLP-1 guide explicitly recommends pairing GLP-1 therapy with resistance training and adequate protein intake (1.0–1.6 g per kg daily) as the two most evidence-backed strategies for preserving lean mass during pharmacological weight loss. This combination — medication for appetite regulation, training for body composition, protein for muscle preservation — is the current standard of care in obesity medicine. Cardiovascular exercise remains beneficial for heart health, metabolic fitness, and mental health, but it does not prevent muscle loss. Prioritize lifting, bodyweight exercises, or resistance bands alongside whatever cardio you enjoy.

What is the difference between GLP-1 supplements and GLP-1 medications?

This distinction matters because it is the single biggest source of consumer confusion in this space. GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved prescription drugs that contain synthetic GLP-1 receptor agonists. They produce clinically significant weight loss (7–24% of body weight; Stanford Medicine). GLP-1 supplements are dietary supplements that do not contain semaglutide, tirzepatide, or any GLP-1 receptor agonist. They cannot replicate the clinical effect of GLP-1 medications.

What well-formulated GLP-1 companion supplements can do is address the nutritional consequences of being on a GLP-1 medication: replenishing B12, iron, zinc, and magnesium; supporting digestive comfort with probiotics and digestive enzymes; and providing ingredients like ginger that have evidence for reducing nausea. The honest framing: GLP-1 medications are the treatment. GLP-1 companion supplements are nutritional support for people already on the treatment. They serve different roles and should not be confused with each other.

Is GLP-1 safe long-term?

The long-term safety profile of GLP-1 receptor agonists is still being established, but the evidence accumulated over 20 years of clinical use and major cardiovascular outcome trials is broadly reassuring.

Cardiovascular safety is a strength, not a concern. The SELECT trial (semaglutide) and SURPASS-CVOT (tirzepatide) both demonstrated significant reductions in major adverse cardiovascular events (MACE): heart attack, stroke, and cardiovascular death. The 2025 comprehensive review found 14–20% MACE reduction across GLP-1 receptor agonist trials. (SELECT and SURPASS-CVOT data).

Pancreatitis and pancreatic cancer. Early concerns have been "dispelled by long-term clinical trials," according to the 2026 PMC safety review.

Thyroid cancer. GLP-1 receptor agonists caused thyroid C-cell tumors in rodents at high doses. This has not been replicated in human studies to date, but the drugs remain contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN 2.

Kidney function. Emerging data suggest potential renoprotective effects, particularly in patients with diabetic kidney disease. This is an area of active research.

Watch: a Stanford endocrinologist on GLP-1 weight-loss drugs

Stanford Medicine endocrinologist Sun Kim, MD, walks through how GLP-1 medications actually work, who they are for, and what the clinical evidence says about long-term use. Covers the difference between semaglutide and tirzepatide, realistic expectations for weight loss, and how to evaluate whether a GLP-1 medication is appropriate for you.

Why YourHealthier

We do not prescribe GLP-1 medications — that is your physician's role. What we noticed is that millions of people starting these drugs have nutritional questions the prescribing visit does not always cover: what to eat when you are not hungry, which vitamins to supplement when your intake drops, how to manage the nausea and GI discomfort. Those are supplement and nutrition questions, and they are exactly what we do. Our GLP-1 Companion supplement was formulated with the specific nutritional gaps GLP-1 therapy creates — B12, iron, zinc, digestive enzymes, probiotics, ginger for nausea support — reviewed by our medical team and third-party tested at accredited laboratories. It is not a replacement for your medication. It is designed to help you tolerate it better and maintain nutritional adequacy while your appetite is suppressed.

Frequently asked questions

Related reading

• Best Supplements for GLP-1 / Ozempic Users
• Berberine: Benefits for Blood Sugar and Metabolism
• Magnesium Glycinate: 7 Benefits Over Other Forms
• Magnesium Glycinate Dosage: How Much by Goal
• Best Time to Take Magnesium Glycinate
• 9 Magnesium Deficiency Symptoms
• Best Electrolyte Powder: LMNT vs Alternatives
• What Are Electrolytes?
• Does Creatine Make You Gain Weight?
• Best Supplement Stacks

Authoritative Resources

For independent, government-reviewed information on GLP-1 medications, consult these primary sources:

• FDA — Medications Containing Semaglutide
• NIH — GLP-1 Receptor Agonists (StatPearls)
• CDC — Adult Obesity Facts

Testing & Transparency Methodology

Every YourHealthier product referenced here is manufactured in an FDA-registered facility and undergoes independent third-party testing at accredited laboratories (ISO/IEC 17025, A2LA, or Eurofins, depending on the product). Each batch is screened for heavy metals (lead, cadmium, mercury, arsenic) and microbial contamination (total plate count, yeast, mold, E. coli, Salmonella) using validated USP, AOAC, and ICP-MS methods. Batch-specific certificates of analysis are published at yourhealthier.com/pages/lab-results and updated with each new manufacturing run. All testing complies with current Good Manufacturing Practices (21 CFR Part 111). This article is written for general educational purposes and is not medical advice; it has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

References

1. Emerging Frontiers in GLP-1 Therapeutics. Systematic review spanning PubMed, Embase, Cochrane. PMC. 2025. PMC
2. The science of safety: adverse effects of GLP-1 receptor agonists. PMC. 2026. PMC
3. Stanford Medicine. GLP-1s 101: What the science says. 2026. Stanford
4. Rojas Lopez RF, et al. Alopecia as an Emerging Adverse Effect Associated With GLP-1 RAs. Cureus. 2025;17(8):e90021. PubMed
5. Functional and Aesthetic Periorbital Changes Linked to GLP-1 RAs. PMC. 2026. PMC
6. Stewart A, Carr B. Theoretical Mechanisms of GLP-1 RA-Induced Depression. European Psychiatry. 2025. PubMed
7. Nutritional Priorities to Support GLP-1 Therapy for Obesity (ACLM / ASN / OMA / TOS Joint Advisory). ScienceDirect. 2024. ScienceDirect

Dietary supplements do not replace GLP-1 medications and are not a substitute for a prescriber’s care. Never start, stop, or change a prescription based on information in this article. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice.

GLP-1 at a Glance

Metric	Value
Weight loss (clinical trials)	7-24% of body weight
Tirzepatide (Zepbound)	~20-22.5%
Semaglutide (Wegovy)	~15%
Nausea (most common SE)	20-44% of users
Regain after stopping	~2 lb/month
MACE reduction	14-20%

Chart: GLP-1 at a Glance. Data: Weight loss in clinical trials: 7-24% of body weight; Tirzepatide (Zepbound): ~20-22.5%; Semaglutide (Wegovy): ~15%; Nausea, the most common side effect: 20-44% of users; Weight regain after stopping: ~2 lb per month; Major adverse cardiovascular event reduction: 14-20%. yourhealthier.com